Zim Laboratories Ltd has scheduled a physical one-on-one meeting with Florintree Trinex LLP on June 19, 2026. The interaction is part of the company's ongoing engagement with investors and analysts, though no unpublished price sensitive information will be disclosed during the session.

The meeting details were disclosed in a filing submitted to BSE Limited and National Stock Exchange of India Limited on June 15, 2026. The company confirmed that the schedule is subject to change due to exigencies.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Piyush Siddheshwar Nikhade, Company Secretary and Compliance Officer, signed the filing on behalf of Zim Laboratories Limited.

ZIM Laboratories Limited has scheduled its 42nd Annual General Meeting (AGM) for June 29, 2026, at 11:30 A.M. IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company filed its Annual Report for FY26 on June 5, 2026, with BSE Limited and National Stock Exchange of India Limited pursuant to Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report details a financial performance characterised by a significant decline in profitability and strategic efforts to restore EU-GMP accreditation.

AGM Details and Key Agenda

The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday, June 23, 2026, to Monday, June 29, 2026 (both days inclusive) for the purpose of the AGM. The remote e-voting period begins on Friday, June 26, 2026, at 9:00 A.M. and ends on Sunday, June 28, 2026, at 5:00 P.M. The cut-off date for determining eligible shareholders for e-voting is June 22, 2026. The deemed venue for the AGM shall be the registered office of the Company at Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Nagpur – 440013, Maharashtra.

The key agenda items for the AGM include the following:

Ms. Roshni Jethani, Company Secretary in Practice, has been appointed as the Scrutinizer to scrutinize the remote e-voting and e-voting process on the date of the AGM.

FY26 Financial Performance

The company reported a sharp contraction in profitability for FY26. Total Operating Income stood at ₹3,744 Mn, a marginal decline of 1.2% from ₹3,790 Mn in the previous year. Profit After Tax (PAT) fell significantly to ₹58 Mn from ₹1,216 Mn in FY25, with PAT margins contracting to 1.6% from 3.2%. EBITDA declined by 16.4% year-on-year to ₹414 Mn. The following table summarises the key financial metrics:

Exports remained the primary revenue driver, contributing 84% of Total Operating Income at ₹3,150 Mn, while domestic revenues accounted for 16%. Finance costs increased from ₹114 Mn to ₹132 Mn in FY26, reflecting an increase in total borrowings from ₹1,122 Mn to ₹1,230 Mn, deployed towards plant and equipment upgrades in support of infrastructure expansion.

Strategic Priorities and Capital Allocation

The company's foremost strategic priority for FY27 is the restoration of EU-GMP accreditation to unlock European market entry. In June 2025, an EU-GMP audit identified deficiencies in manual control and documentation processes, leading to a pause in accreditation. The company submitted CAPA responses encompassing manpower reinforcement, investment in new plant and equipment, and a comprehensive overhaul of systems and processes, which have been formally accepted by the remediation committee and auditors. ZIM completed a preferential issue of 47,64,497 equity shares at an issue price of ₹73.46 per share to Florintree Trinex LLP, raising approximately ₹350 million. These funds are being deployed towards CAPA remediation infrastructure, completing the dedicated NIP suite for EU business, and expanding the Nutraceuticals suite.

Business Segment and Geographic Performance

The Pharmaceuticals division continued to be the primary revenue driver, accounting for 80% of Total Operating Income at ₹2,990 Mn, while the Nutraceuticals division contributed 20% at ₹754 Mn. Geographically, the Americas and MENA were the largest markets at ₹1,298 Mn each, followed by Asia (excluding India) at ₹1,123 Mn and India at ₹594 Mn. The company completed 57 regulatory filings across key geographies, comprising 14 NIP filings, 29 OTF filings, and 14 FF filings.

Director Remuneration and Shareholding

For FY 2025-26, the remuneration paid to executive directors is detailed below:

The proposed remuneration range for the Managing Director is a fixed salary of ₹130.00 Lakhs p.a. to ₹300.00 Lakhs p.a., plus commission on profit up to 2.0% of the net profits of the Company p.a. For the Whole-Time Director (Mr. Zulfiquar Kamal), the proposed fixed pay range is ₹87.50 Lakhs p.a. to ₹250.00 Lakhs p.a., plus commission on profit up to 1.0% of the net profits of the Company p.a. The securities held by the directors as on March 31, 2026, are as follows:

R&D and Innovation

Research and Development expenditure for FY26 was ₹311 Mn, representing 8.3% of Total Operating Income. The company has invested a total of ₹1,503 Mn in R&D over the last five years on Opex, Facility, and BE studies. Development of all 12 NIP products is complete, and the company is in advanced Bio-Equivalence studies for select products. The focus remains on advancing patient-centric drug delivery solutions and strengthening its presence in Developed and Pharmerging markets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE518E01015/208b8668c4804404.pdf